» Articles » PMID: 20519625

Human Gammadelta T Lymphocytes Induce Robust NK Cell-mediated Antitumor Cytotoxicity Through CD137 Engagement

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2010 Jun 4
PMID 20519625
Citations 118
Authors
Affiliations
Soon will be listed here.
Abstract

Natural killer (NK) cells are innate effector lymphocytes that control the growth of major histocompatibility complex class I negative tumors. We show here that γδ T lymphocytes, expanded in vitro in the presence isopentenylpyrophosphate (IPP), induce NK cell-mediated killing of tumors that are usually resistant to NK cytolysis. The induction of cytotoxicity toward these resistant tumors requires priming of NK cells by immobilized human immunoglobulin G1 and costimulation through CD137L expressed on activated γδ T lymphocytes. This costimulation increases NKG2D expression on the NK-cell surface, which is directly responsible for tumor cell lysis. Moreover, culturing peripheral blood mononuclear cells with zoledronic acid, a γδ T lymphocyte activating agent, enhances NK-cell direct cytotoxicity and antibody-dependent cellular cytotoxicity against hematopoietic and nonhematopoietic tumors. Our data reveal a novel function of human γδ T lymphocytes in the regulation of NK cell-mediated cytotoxicity and provide rationale for the use of strategies to manipulate the CD137 pathway to augment innate antitumor immunity.

Citing Articles

Prognostic signature detects homologous recombination deficient in glioblastoma.

Luo D, Luo A, Hu S, Zhao H, Yao X, Li D Transl Cancer Res. 2024; 13(11):5883-5897.

PMID: 39697739 PMC: 11651736. DOI: 10.21037/tcr-23-2077.


Solute carrier family 4 member 4 (SLC4A4) is associated with cell proliferation, migration and immune cell infiltration in colon cancer.

Yu C, Li H, Zhang C, Tang Y, Huang Y, Lu H Discov Oncol. 2024; 15(1):597.

PMID: 39467887 PMC: 11519258. DOI: 10.1007/s12672-024-01488-x.


Research Progress of γδT Cells in Tumor Immunotherapy.

Li Y, Mo X, Yao H, Xiong Q Cancer Control. 2024; 31:10732748241284863.

PMID: 39348473 PMC: 11459529. DOI: 10.1177/10732748241284863.


Potential of gamma/delta T cells for solid tumor immunotherapy.

Zhu D, Ren X, Xie W, Chen J, Liang S, Jiang M Front Immunol. 2024; 15:1466266.

PMID: 39253082 PMC: 11381238. DOI: 10.3389/fimmu.2024.1466266.


Natural killer cells and engagers: Powerful weapons against cancer.

Bottino C, Picant V, Vivier E, Castriconi R Immunol Rev. 2024; 328(1):412-421.

PMID: 39180430 PMC: 11659922. DOI: 10.1111/imr.13384.


References
1.
Assarsson E, Carbone E, Karre K, Ljunggren H . Triggering of murine NK cells by CD40 and CD86 (B7-2). J Immunol. 1999; 162(10):5910-6. View

2.
Bank I, Book M, Huszar M, Baram Y, Schnirer I, Brenner H . V delta 2+ gamma delta T lymphocytes are cytotoxic to the MCF 7 breast carcinoma cell line and can be detected among the T cells that infiltrate breast tumors. Clin Immunol Immunopathol. 1993; 67(1):17-24. DOI: 10.1006/clin.1993.1040. View

3.
Cerwenka A, Lanier L . Natural killer cells, viruses and cancer. Nat Rev Immunol. 2002; 1(1):41-9. DOI: 10.1038/35095564. View

4.
Kabelitz D, Wesch D, Pitters E, Zoller M . Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol. 2004; 173(11):6767-76. DOI: 10.4049/jimmunol.173.11.6767. View

5.
Tamada K, Chen L . Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules. Cancer Immunol Immunother. 2005; 55(4):355-62. PMC: 11030687. DOI: 10.1007/s00262-005-0081-y. View